assieme
simesa s.p.a. - formoterolo e budesonide - formoterolo e budesonide
ambroxolo almus
almus s.r.l. - ambroxolo - ambroxolo
osmohale
pharmaxis europe limited - altri diagnostici - altri diagnostici
chenpen
bioprojet pharma - adrenalina - adrenalina
buscopan
medifarm s.r.l. - butilscopolamina bromuro - butilscopolamina bromuro
carbidopa e levodopa accord
accord healthcare limited - levodopa e inibitori della decarbossilasi - levodopa e inibitori della decarbossilasi
buscopan
gekofar s.r.l. - butilscopolamina bromuro - butilscopolamina bromuro
oxivent
boehringer ingelheim italia s.p.a. - ossitropio bromuro - ossitropio bromuro
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - farmaci per le malattie respiratorie ostruttive, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).
bretaris genuair
covis pharma europe b.v. - aclidinium bromide - malattia polmonare, ostruttiva cronica - farmaci per le malattie respiratorie ostruttive, - bretaris genuair è indicato come trattamento broncodilatatore di mantenimento per alleviare i sintomi in pazienti adulti con malattia polmonare ostruttiva cronica (bpco).